Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by NorthStarron Jun 15, 2010 2:16pm
449 Views
Post# 17190765

RE: RE: RE: Something wierd on TD

RE: RE: RE: Something wierd on TDSenior Loki,  


Here is from my QuestTrade account....   ( hope stockhouse does not butcher the columns to badly for you. )

EPS (TTM)
-0.03
(not sure what the TTM stands for)


Quaterly Income      in Thousands of Dollars
03/2010     12/2009     09/2009
Operating Revenue                                                -                    -                    -
Adjustments to Revenue                                      -                     -                    -
Cost of Revenue                                                    -                      -                   (0)
Gross Operating Profit                                          -                       -                  (0)
Selling/General/Admin Expense                      (676)         (895)               (366)
Research & Development                                 (542)          (658)              (854)
EBITDA                                                                  (1,217)     (1,553)          (1,220)
Depreciation & Amortization                             (65)               (66)                 (68)
Operating Income                                               (1,283)     (1,619)          (1,287)
Other Income, Net                                              (9)                  (18)              (44)
Interest Expense                                                 -                         -                  -
Pre-Tax Income                                                  (1,292)         (1,288)        (1,495)
Income Taxes                                                        -                       -                  -
Minority Interest                                                    -                         -                 -
Net Income from Continuing Operations       (1,292)      (1,288)          (1,495)
Net Income from Discontinued Operations         -         -
Net Income from Total Operations                  (1,292)     (1,288)           (1,495)
Normalized Income                                           (1,292)        (1,632)         (1,331)
Extraordinary Income                                           -                       -                    -
Special Income/Charges                                    -                   344               (165)
Income from Cum. Effect of Acct Change         -         -         -
Income from Tax Loss Carryforward                -         -         -
Other Gains                                                          --         -         -
Total Net Income                                                (1,292)        (1,288)        (1,495)

Results in Dollars (Preferred Dividends in Thousands)
03/2010     12/2009     09/2009
Dividends Paid Per Share                                  0.00                0.00         0.00
Preferred Dividends                                                    -                     -          -
Basic EPS from Continuing Operations             -0.01            0.00         -0.01
Basic EPS from Discontinued Operations          0.00           0.00           0.00
Basic EPS from Total Operations                         -0.01          0.00         -0.01
Diluted EPS from Continuing Operations            -0.01         0.00         -0.01
Diluted EPS from Discontinued Operations          0.00         0.00        0.00
Diluted EPS from Total Operations                         - 0.01       0.00         -0.01



Quaterly CASH FLOW                           03/2010

Net Income                                               (1,292)
Depreciation & Amortization                   5
Deferred Income Taxes                           -
Operating Losses                                     9
Extraordinary Losses                                -
Decrease in Receivables                        68
Decrease in Inventories                             -
Decrease in Other Current Assets          -
Increase in Payables                            (214)
Increase in Other Current Liabilities    -
Decrease in Other Working Capital     -
Other Non-Cash Items                            182
Net Cash from Continuing Operations     (1,171)
Net Cash from Discontinued Operations     -
Cash from Operating Activities                   (1,171)
Sale of Property, Plant, Equipment              -
Sale of Long Term Investments     -     -
Sale of Short Term Investments     -     -
Purchase of Property, Plant, Equipment     -
Acquisitions     -     -     -     -
Purchase of Long Term Investments     -
Purchase of Short Term Investments     -
Other Investment Changes, Net              -     -
Cash from Investing Activities                    -     -
Issuance of Debt                                       -     -     -
Issuance of Capital Stock                        15
Repayment of Debt                                     (1)
Repurchase of Capital Stock                       -
Payment of Cash Dividends                        -
Other Financing Charges, Net                (0)
Cash from Financing Activities              14
Effect of Exchange Rate Changes         (9)
Net Change in Cash                            (1,167)
Cash at Beginning of Year                   4,506
Cash at End of Period                            3,339


North

Bullboard Posts